CA2245162A1 - Procede de traitement et composition pharmaceutique - Google Patents

Procede de traitement et composition pharmaceutique Download PDF

Info

Publication number
CA2245162A1
CA2245162A1 CA002245162A CA2245162A CA2245162A1 CA 2245162 A1 CA2245162 A1 CA 2245162A1 CA 002245162 A CA002245162 A CA 002245162A CA 2245162 A CA2245162 A CA 2245162A CA 2245162 A1 CA2245162 A1 CA 2245162A1
Authority
CA
Canada
Prior art keywords
phenyl
loratadine
pharmaceutical formulation
sodium
leukotriene antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002245162A
Other languages
English (en)
Inventor
Sven-Erik Dahlen
Edward M. Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en
Application filed by Individual filed Critical Individual
Publication of CA2245162A1 publication Critical patent/CA2245162A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ce procédé de traitement de l'asthme, de l'allergie et de l'inflammation consiste à traiter ces manifestations à l'aide d'un inhibiteur des leucotriènes, ainsi que de loratadine, par administration simultanée de ceux-ci, soit sous des doses séparées, soit sous des doses combinées en une seule formulation pharmaceutique.
CA002245162A 1996-02-08 1997-02-04 Procede de traitement et composition pharmaceutique Abandoned CA2245162A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1132896P 1996-02-08 1996-02-08
US60/011,328 1996-02-08
GBGB9608927.1A GB9608927D0 (en) 1996-04-29 1996-04-29 Method of treatment and pharmaceutical composition
GB9608927.1 1996-04-29

Publications (1)

Publication Number Publication Date
CA2245162A1 true CA2245162A1 (fr) 1997-08-14

Family

ID=26309231

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002245162A Abandoned CA2245162A1 (fr) 1996-02-08 1997-02-04 Procede de traitement et composition pharmaceutique

Country Status (19)

Country Link
EP (1) EP1014972A4 (fr)
JP (1) JPH11504044A (fr)
KR (1) KR19990082367A (fr)
CN (1) CN1210465A (fr)
AU (1) AU732671B2 (fr)
BG (1) BG102669A (fr)
BR (1) BR9707369A (fr)
CA (1) CA2245162A1 (fr)
CZ (1) CZ248798A3 (fr)
EE (1) EE9800234A (fr)
IL (1) IL125446A0 (fr)
IS (1) IS4805A (fr)
NO (1) NO983641D0 (fr)
NZ (1) NZ331160A (fr)
PL (1) PL328074A1 (fr)
SK (1) SK105698A3 (fr)
TR (1) TR199801511T2 (fr)
WO (1) WO1997028797A1 (fr)
YU (1) YU33298A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301349B6 (cs) * 1997-12-23 2010-01-27 Schering Corporation Prostredek k lécbe respiracních a kožních onemocnení, který obsahuje alespon jednoho antagonistu leukotrienu a alespon jedno antihistaminikum

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
PE20001070A1 (es) * 1998-09-10 2000-10-19 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
WO2002036124A2 (fr) * 2000-10-30 2002-05-10 Schering Corporation Procede de traitement
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
WO2004087095A2 (fr) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositif osmotique contenant du zafirlukast et un antagoniste h1
EP1680084A2 (fr) * 2003-10-21 2006-07-19 Direct-Haler A/S Medication a administration par voies multiples, servant a traiter une rhinite et un asthme
WO2005089748A1 (fr) * 2004-03-17 2005-09-29 Pfizer Limited Combinaison pour traitement de maladies inflammatoires
JP2008517938A (ja) 2004-10-25 2008-05-29 シェーリング コーポレイション 呼吸器障害を処置するために他の活性剤と組み合わせたｍ１レセプターアンタゴニストおよび／またはｍ３レセプターアンタゴニスト
TR200806298A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
JP2012530140A (ja) 2009-06-16 2012-11-29 メルク・シャープ・アンド・ドーム・コーポレーション グルココルチコイド受容体アゴニストとしての新規［３，２−ｃ］ヘテロアリールステロイド、組成物およびこの使用
KR101540191B1 (ko) * 2014-02-24 2015-07-28 성균관대학교산학협력단 로라타딘을 포함하는 항염증용 조성물
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (fr) * 1984-08-20 1989-09-26 Masaaki Toda Benz(thio) amides fusionnes
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301349B6 (cs) * 1997-12-23 2010-01-27 Schering Corporation Prostredek k lécbe respiracních a kožních onemocnení, který obsahuje alespon jednoho antagonistu leukotrienu a alespon jedno antihistaminikum

Also Published As

Publication number Publication date
CZ248798A3 (cs) 1999-01-13
IS4805A (is) 1998-07-22
BR9707369A (pt) 1999-07-20
JPH11504044A (ja) 1999-04-06
YU33298A (en) 1999-11-22
EP1014972A1 (fr) 2000-07-05
BG102669A (bg) 1999-04-30
NO983641L (no) 1998-08-07
TR199801511T2 (xx) 1998-10-21
CN1210465A (zh) 1999-03-10
NZ331160A (en) 2000-07-28
AU732671B2 (en) 2001-04-26
NO983641D0 (no) 1998-08-07
EP1014972A4 (fr) 2004-12-08
PL328074A1 (en) 1999-01-04
WO1997028797A1 (fr) 1997-08-14
AU2257997A (en) 1997-08-28
EE9800234A (et) 1998-12-15
KR19990082367A (ko) 1999-11-25
SK105698A3 (en) 1999-05-07
IL125446A0 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
CA2245162A1 (fr) Procede de traitement et composition pharmaceutique
CA2315721C (fr) Composition pour le traitement de maladies respiratoires et cutanees, comprenant au moins un antagoniste de leucotriene et au moins un antihistamine
AU781177B2 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
RU2423106C2 (ru) Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
TW201035071A (en) Enhanced migraine treatments based on ghrelin mimetics
CA3238102A1 (fr) Traitement de troubles hepatiques avec un inhibiteur de ssao
JP2008517938A (ja) 呼吸器障害を処置するために他の活性剤と組み合わせたｍ１レセプターアンタゴニストおよび／またはｍ３レセプターアンタゴニスト
US6372197B1 (en) Methods and compositions using norastemizole in combination with leukotriene inhibitors
TW202541793A (zh) 用於預防貓之全身性疾病之血管緊張素ii受體拮抗劑
CA2328074A1 (fr) Methodes et compositions d'utilisation de metabolites de terfenadine en combinaison avec des inhibiteurs de leucotriene
US20070275996A1 (en) Use of Statins For The Treatment Of Metabolic Syndrome
US6902746B2 (en) Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
HK1018744A (en) Method of treatment and pharmaceutical composition
HK40066392A (zh) Aerd/哮喘中的血栓烷受体拮抗剂
KR20010052895A (ko) 치료 방법
JP2023544224A (ja) ヒト低コリン作動性障害の処置のための医薬の組合せ
CN1149828A (zh) 过敏性鼻炎的治疗方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued